Monopar Therapeutics Inc (MNPR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Monopar Therapeutics Inc stock (MNPR) is currently trading at $56.95. Analyst consensus price target for MNPR is $112.00. WallStSmart rates MNPR as Sell.
- MNPR PE ratio analysis and historical PE chart
- MNPR PS ratio (Price-to-Sales) history and trend
- MNPR intrinsic value — DCF, Graham Number, EPV models
- MNPR stock price prediction 2025 2026 2027 2028 2029 2030
- MNPR fair value vs current price
- MNPR insider transactions and insider buying
- Is MNPR undervalued or overvalued?
- Monopar Therapeutics Inc financial analysis — revenue, earnings, cash flow
- MNPR Piotroski F-Score and Altman Z-Score
- MNPR analyst price target and Smart Rating
Monopar Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Monopar Therapeutics Inc (MNPR) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity. Significant fundamental concerns warrant caution or avoidance.
Monopar Therapeutics Inc (MNPR) Key Strengths (1)
83.27% of shares held by major funds and institutions
Supporting Valuation Data
Monopar Therapeutics Inc (MNPR) Areas to Watch (3)
Company is destroying shareholder value
Small-cap company with higher risk but more growth potential
Fairly priced relative to book value
Monopar Therapeutics Inc (MNPR) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 1 register as strengths (avg 10.0/10) while 3 fall into concern territory (avg 3.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Market Cap, Price/Book. Some valuation metrics including Price/Book (2.61) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -26.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -26.50% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Market Cap are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
MNPR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
MNPR's Price-to-Sales ratio of 2983.97x trades 269% above its historical average of 809.14x (90th percentile), historically expensive. The current valuation is 37% below its historical high of 4705.12x set in Nov 2025, and 17641% above its historical low of 16.82x in Nov 2023. Over the past 12 months, the PS ratio has expanded from ~2201.9x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Monopar Therapeutics Inc (MNPR) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Monopar Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Debt-to-equity ratio of 0.00 indicates a conservative balance sheet with 128M in cash.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 1.67, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Monopar Therapeutics Inc.
Bottom Line
Monopar Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Monopar Therapeutics Inc(MNPR)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to developing proprietary therapies to improve clinical outcomes for cancer patients in the United States. The company is headquartered in Wilmette, Illinois.